FDA Adds Intestinal Blockage Risk to Ozempic Label, Similar Drugs Also Implicated

The U.S. Food and Drug Administration (FDA) has updated the label for Ozempic, a type 2 diabetes drug commonly used for weight loss, to include a warning about the potential side effect of intestinal blockage. The FDA acknowledged increased reports of ileus, or the blockage of intestinal contents, associated with the drug's active ingredient, semaglutide. The labeling changes also apply to Wegovy, another weight loss drug made by the same manufacturer. This update comes after a lawsuit was filed against Novo Nordisk and Eli Lily, alleging that the drug makers failed to adequately warn patients about the risk of severe gastrointestinal problems associated with their medications.